AMRI is expanding its nuclear magnetic resonance (NMR) spectroscopy capabilities in Europe with the addition of the Bruker AVANCE NEO 600 MHz NMR Spectrometer.
“NMR is a core technology of our analytical services offering. Our investment in this state-of-the-art spectrometer reflects our continued commitment to provide our world-class solutions to our customers across the globe,” said Ana Maria de la Parte, AMRI site head, Valladolid, Spain.

The Bruker AVANCE NEO 600 MHz NMR provides enhanced productivity for delivering high quality NMR data with increased sensitivity utilizing a cryoprobe. This capability will also allow AMRI to support the FDA requirements for biosimilarity testing and USP (e.g., heparin) testing requiring higher field NMR.

The new 600 MHz NMR spectrometer, which will be operational in late 2018, provides access to high-quality data as a stand-alone service offering and will enhance the information that AMRI delivers from other chemistry services including polymorph, salt and cocrystal screens.